Results 21 to 30 of about 75,066 (195)

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

Multicomponent Stapling of Glucagon‐Like Peptide‐1 Enables Receptor‐Guided PROTAC Delivery

Angewandte Chemie, EarlyView.
We report a stapled glucagon‐like peptide‐1 (GLP‐1) analogue created via multicomponent tryptophan‐mediated Petasis reaction (TMPR). This strategy yields a stabilised peptide with superior helicity and improved potency. Conjugation to a bromodomain‐containing protein 4 (BRD4) degrader creates the first GLP‐1‐guided targeted protein degrader (PROTAC ...
Jan L. Venne, Sona Krajcovicova, Graeme Davies, Hannah Bolt, Jefferson Revell, David R. Spring   +5 more
wiley   +2 more sources

Glucagon-like peptide-1 analogues: An overview

Indian Journal of Endocrinology and Metabolism, 2013
Abnormalities of the incretin axis have been implicated in the pathogenesis of type 2 diabetes mellitus. Glucagon-like peptide-1 (GLP-1) and gastroinhibitory intestinal peptide constitutes >90% of all the incretin function.
Vishal Gupta
doaj   +1 more source

New perspectives on the use of glucagon-like peptide 1 in diseases of the central nervous system

Current Issues in Pharmacy and Medical Sciences, 2023
Glucagon-like peptide 1 is a neuromodulatory peptide that regulates the carbohydrate metabolism. It can cross the blood-brain barrier, and, indeed, while mostly produced in the distal small intestine and colon, it is also synthesized in the nucleus of ...
Lupina Malgorzata, Listos Joanna
doaj   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

Adipocyte‐Derived Leptolin Enhances Energy Expenditure and Prevents Obesity

Advanced Science, EarlyView.
We identified a novel adipokine, which we named leptolin. In humans, leptolin levels in white adipose tissue were positively correlated with exercise and negatively associated with body mass index. We observed elevated leptolin in serum from athletes and lower leptolin in serum from obese individuals.
Jiarui Liu, Bingwei Wang, Zhijie Su, Xiaoxv Han, Miao He, Yun Zhao, Yujia Hou, Daotong Li, Weiguang Zhang, Lihua Qin, Ke Wang, Yanchun Li, Yi Yan, Siwang Yu, Xiaoshuai Huang, Tairan Yuwen, Jianyuan Luo, Ruimao Zheng   +17 more
wiley   +1 more source

Canagliflozin Alleviates Diabetic Glomerular Endothelial Injury via Melibiose in a Microbiota‐Dependent Manner

Advanced Science, EarlyView.
Canagliflozin treatment reshapes the gut microbiota in DKD and elevates levels of melibiose, a metabolite derived from Roseburia intestinalis. Melibiose directly binds to and enhances the enzymatic activity of glyoxalase 1, leading to decreased methylglyoxal accumulation.
Wei Zhang, Yi Song, Changkun Li, Yuanyuan Luo, Mingwei Shao, Feng Guo, Fangyi Wei, Xunjie Fan, Wenwen Guo, Fengmei Xu, Yanhong Sang, Dongming Zhang, Yanhong Zhou, Lianwei Wang, Zhiqiang Kang, Yingjun Yang, Chunhua Song, Yanxia Liu, Xiaojun Ma, Jiao Wang, Chong Li, Shengnan Ma, Lin Zhao, Zhi Qin, Guolan Xing, Qiubo Zhao, Jun Li, Shumin Song, Dan Zhao, Ting Huang, Qingzhu Wang, Yanyan Zhao, Guijun Qin   +32 more
wiley   +1 more source

Dermatological Manifestations of Glucagon‐Like Peptide‐1 Receptor Agonists

JEADV Clinical Practice
Background Glucagon‐like peptide‐1 receptor agonists (GLP‑1 RAs) play a pivotal role in treating type 2 diabetes. Despite their widespread use, their dermatological manifestations remain under‐recognized, hence the interest of this systematic review ...
Nour Ghostine, Maya Halabi‐Tawil
doaj   +1 more source

An Implantable Optogenetics‐Engineered Hydrogel for Amelioration of Rheumatoid Arthritis through Light‐Controlled Metabolic Reprogramming of Synovial Macrophages

Advanced Science, EarlyView.
An implantable hydrogel is designed to enable in situ and on‐demand secretion of GLP‐1 in synovium through blue light irradiation to activate GLP‐1R/HK2/VDAC1 pathway for upregulating tricarboxylic acid cycle and oxidative phosphorylation in macrophage, facilitating tissue repair and bone erosion recovery.
Dahai Hu, Yaru Sun, Qi Lu, Yi Zhang, Jieruo Li, Huige Hou, Huajun Wang, Hui Tang, Yunsong Zhang, Xiaofei Zheng, Qingsong Mei   +10 more
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonists and kidney outcomes

Journal of Diabetes
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of
Richard J. MacIsaac, Philippa Trevella, Elif I. Ekinci   +2 more
doaj   +1 more source